Our daily activities require vigilance. Therefore, it is useful to externally monitor and predict our vigilance level using a straightforward method. It is known that the vigilance level is linked to pupillary fluctuations via Locus Coeruleus and Norepinephrine (LC-NE) system. However, previous methods of estimating long-term vigilance require monitoring pupillary fluctuations at rest over a long period. We developed a method of predicting the short-term vigilance level by monitoring pupillary fluctuation for a shorter period consisting of several seconds. The LC activity also fluctuates at a timescale of seconds. Therefore, we hypothesized that the short-term vigilance level could be estimated using pupillary fluctuations in a short period and quantified their amplitude as the Micro-Pupillary Unrest Index (M-PUI). We found an intra-individual trial-by-trial positive correlation between Reaction Time (RT) reflecting the short-term vigilance level and M-PUI in the period immediately before the target onset in a Psychomotor Vigilance Task (PVT). This relationship was most evident when the fluctuation was smoothed by a Hanning window of approximately 50 to 100 ms (including cases of down-sampled data at 100 and 50 Hz), and M-PUI was calculated in the period up to one or two seconds before the target onset. These results suggest that M-PUI can monitor and predict fluctuating levels of vigilance. M-PUI is also useful for examining pupillary fluctuations in a short period for elucidating the psychophysiological mechanisms of short-term vigilance.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448328PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0256953PLOS

Publication Analysis

Top Keywords

vigilance level
24
short-term vigilance
20
pupillary fluctuations
16
vigilance
12
pupillary fluctuation
8
psychomotor vigilance
8
monitor predict
8
monitoring pupillary
8
fluctuations short
8
short period
8

Similar Publications

Contemporary studies report nonconvulsive status epilepticus (NCSE) in Creutzfeldt-Jakob disease (CJD), based on benzodiazepine (BZP)-responsive epileptiform discharges on the electroencephalogram (EEG), with the following false syllogism: (1) intravenous (IV) administration of BZPs usually suppress ictal activity in NCSE; (2) in CJD, periodic sharp wave complexes (PSWCs) are suppressed by IV BZPs; (3) therefore, these patients have NCSE. This is a simplistic and invalid conclusion, because authors of 20th-century science reports have clearly shown that IV BZPs, short-acting barbiturates, and drugs with no antiseizure effects, such as chloral hydrate and IV naloxone, suppress PSWCs, but patients fall asleep with no clinical improvement. In contrast, IV methylphenidate transiently improves both the EEG and clinical states.

View Article and Find Full Text PDF

Background: In clinical practice, the emergence of ST11-K64 carbapenem-resistant Klebsiella pneumoniae (ST11-K64 CRKP) has become increasingly alarming. Despite this trend, limited research has been conducted to elucidate the clinical and molecular characteristics of these strains.

Objectives: This study aimed to comprehensively investigate the clinical characteristics, antimicrobial resistance patterns, resistance and virulence-associated genes, and molecular epidemiology of ST11-K64 CRKP in Southwest China.

View Article and Find Full Text PDF

Background: Alzheimer's disease is defined by the pathological aggregation of amyloid-beta and hyperphosphorylated tau. AD patients often exhibit other symptoms like metabolic and sleep dysfunction. Currently, it is unclear if impairments are a cause or consequence of Aβ or tau aggregation.

View Article and Find Full Text PDF

Evaluation of two different wrist actigraphy devices in the adult population.

J Clin Sleep Med

January 2025

Departamento de Enfermedades Respiratorias, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

Study Objectives: Actigraphy devices are used in sleep medicine. The Actiwatch 2 (Philips Respironics) was an example of a frequently used device in this field. Nevertheless, the discontinuation of this device has led to an increased necessity for the implementation of other available actigraphy methods capable of providing objective information.

View Article and Find Full Text PDF

A real-world pharmacovigilance study of Sorafenib based on the FDA Adverse Event Reporting System.

Front Pharmacol

December 2024

Department of Gastroenterology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China.

Article Synopsis
  • The study aimed to monitor adverse events (AEs) linked to Sorafenib, a drug used for treating liver, kidney, and thyroid cancers, focusing on enhancing patient safety.
  • Reports from the FDA Adverse Event Reporting System (FAERS) from 2004 to 2024 were analyzed, revealing a total of 18,624 patients and 82,857 AEs across 26 organ systems.
  • The findings included both expected AEs, like diarrhea and fatigue, and unexpected ones, such as gait inability and hyperkeratosis, highlighting the need for ongoing monitoring to identify new reactions and improve patient care.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!